Analysts Offer Predictions for Genmab A/S FY2025 Earnings

Genmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at William Blair decreased their FY2025 EPS estimates for shares of Genmab A/S in a research note issued on Tuesday, January 21st. William Blair analyst M. Phipps now expects that the company will post earnings of $1.38 per share for the year, down from their prior estimate of $1.60. The consensus estimate for Genmab A/S's current full-year earnings is $1.28 per share.

Several other equities research analysts have also recently issued reports on the stock. BMO Capital Markets reiterated an "outperform" rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Redburn Atlantic began coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a "buy" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Stock Up 1.5 %

NASDAQ GMAB traded up $0.32 during trading hours on Thursday, reaching $21.29. The company's stock had a trading volume of 860,581 shares, compared to its average volume of 1,107,177. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $31.88. The company has a market capitalization of $14.09 billion, a price-to-earnings ratio of 20.67, a PEG ratio of 0.59 and a beta of 0.97. The firm's 50-day moving average price is $21.07 and its 200-day moving average price is $23.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million during the quarter, compared to analysts' expectations of $838.20 million. During the same quarter in the previous year, the firm earned $0.47 earnings per share.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. Legacy Wealth Asset Management LLC boosted its position in shares of Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company's stock valued at $1,097,000 after buying an additional 471 shares during the period. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock worth $182,000 after acquiring an additional 478 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after acquiring an additional 1,051 shares during the period. Eagle Asset Management Inc. grew its position in Genmab A/S by 10.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company's stock valued at $285,000 after acquiring an additional 1,121 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Genmab A/S by 7.1% in the second quarter. Rhumbline Advisers now owns 18,694 shares of the company's stock worth $470,000 after purchasing an additional 1,236 shares during the period. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.